With the objective of applying an alternative model for drug research and development for the most neglected diseases, at DNDi we strive to hold ourselves to the highest standards of accountability, transparency, ethics, and best practice in all we do, internally and programmatically. DNDi’s Board of Directors approves project selection and sets policies governing intellectual property, financial control, and ethics.

All of DNDi’s clinical programmes are guided by international, regional, and local regulations and standards, including Good Clinical Practice guidelines (GCP/ICH) and the Helsinki Declaration , following the basic principles for medical research involving human subjects, and according to the local and external institutional review boards, and local rules and regulations of the countries in which we work.

Our Integrity Line is an online third-party platform that can be used for the anonymous reporting of misconduct by DNDi staff or anyone outside the organization in connection with DNDi activities.

Access Policy

Code of Conduct

• Français
• Learn more about our Code of Conduct
• Learn more about our Integrity Line

Conflict of Interest Policy

Data Protection Policy

Fraud & Corruption Prevention Policy

Fundraising Policy

Guidelines for the Prevention of Sexual Misconduct

Integrated People Strategy

• Español
• Français
• Português

Intellectual Property Policy

Pharmaceutical Quality Policy

Policy on Sharing and Secondary Use of Human Subject Research Data

Privacy Policy

Procurement Policy

Regulatory Policy

Research Misconduct Policy

Safeguarding Dispute Resolution Processes

Scientific & Clinical External Communications Policy